First Time Loading...

Reata Pharmaceuticals Inc
NASDAQ:RETA

Watchlist Manager
Reata Pharmaceuticals Inc Logo
Reata Pharmaceuticals Inc
NASDAQ:RETA
Watchlist
Price: 172.36 USD Market Closed
Updated: May 1, 2024
Section:
 

Wall Street
Price Targets

RETA Price Targets Summary
Reata Pharmaceuticals Inc

Wall Street analysts forecast RETA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RETA is 172.4 USD .

RETA Lowest Forecast
Wall Street Target
Not Available
RETA Average Forecast
Wall Street Target
172.4 USD
0% Upside
RETA Highest Forecast
Wall Street Target
Not Available
Lowest
Price Target
Not Available
Average
Price Target
172.4 USD
0% Upside
Highest
Price Target
Not Available
Reata Pharmaceuticals Inc Competitors:
Price Targets
GRANULES
Granules India Ltd
3% Upside
4502
Takeda Pharmaceutical Co Ltd
19% Upside
1760
Panion & BF Biotech Inc
14% Upside
D
170900
Dong-A ST Co Ltd
30% Upside
GRANULES
Granules India Ltd
3% Upside
4502
Takeda Pharmaceutical Co Ltd
19% Upside
1760
Panion & BF Biotech Inc
14% Upside
D
170900
Dong-A ST Co Ltd
30% Upside
TARS
Tarsus Pharmaceuticals Inc
73% Upside
P
PLTH
Planet 13 Holdings Inc
130% Upside
600276
Jiangsu Hengrui Pharmaceuticals Co Ltd
25% Upside
B
600085
Beijing Tongrentang Co Ltd
43% Upside

Revenue
Forecast

Revenue Estimate
Reata Pharmaceuticals Inc

For the last 8 years the compound annual growth rate for Reata Pharmaceuticals Inc's revenue is -33%. The projected CAGR for the next 3 years is 571%.

-33%
Past Growth
571%
Estimated Growth
Estimates Accuracy
-4%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Reata Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Reata Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-18%
Average Miss
What are analyst estimates?

See Also

Summary
RETA intrinsic value, competitors valuation, and company profile.
DCF Valuation
RETA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
RETA stock valuation using valuation multiples.
Wall Street Estimates
RETA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
RETA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is RETA's stock price target?
Price Target
172.4 USD

According to Wall Street analysts, the average 1-year price target for RETA is 172.4 USD .

What is Reata Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
571%

For the last 8 years the compound annual growth rate for Reata Pharmaceuticals Inc's revenue is -33%. The projected CAGR for the next 3 years is 571%.

ALPHA SPREAD
Join more than 133,100+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.